zoledronic acid has been researched along with Metastase in 92 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 36 (39.13) | 29.6817 |
| 2010's | 49 (53.26) | 24.3611 |
| 2020's | 7 (7.61) | 2.80 |
| Authors | Studies |
|---|---|
| Artioli, F; Bongiovanni, A; Burgio, MA; Fantini, M; Fausti, V; Foca, F; Forcignanò, MR; Guadalupi, V; Ibrahim, T; Menis, J; Mercatali, L; Miserocchi, A; Recine, F; Spadazzi, C; Stucci, SL | 1 |
| George, DJ | 1 |
| Abrams, JS; Barlow, WE; Chew, HK; Clemons, M; Dakhil, SR; Dammann, KZ; Dees, EC; Elias, AD; Falkson, CI; Gralow, JR; Hayes, DF; Hershman, DL; Hortobagyi, GN; Ingle, JN; Lew, DL; Livingston, RB; M'iao, JL; Margolis, JH; Messino, MJ; Paterson, AHG; Schubert, MM; Stopeck, AT; Van Poznak, CH | 1 |
| Chen, G; John, J; Lu, C; Tang, L; Wang, Q | 1 |
| Kajima, M; Makita, C; Manabe, Y; Matsuo, M; Matsuyama, K; Tanaka, H | 1 |
| Drumm, C; Grogan, L; Maguire, M; Mullally, W; O'Kane, M; Redmond, M; Woods, G | 1 |
| Boran, G; Dierking, I; Ege, D; Kamali, AR; Tavakoli, S | 1 |
| George, DJ; Higano, CS; Jiao, X; Kalinovsky, J; Miller, K; Saad, F; Sartor, O; Shore, N; Sternberg, CN; Tangirala, K; Tombal, B | 1 |
| Hashida, T; Hirabatake, M; Ikemura, M; Ikesue, H; Ishikawa, T; Katoh, H; Kawakita, M; Mouri, M; Muroi, N; Takenobu, T; Tomii, K; Tomita, H; Yamamoto, S; Yasui, H | 1 |
| Jun, JH | 1 |
| Cao, Q; Chen, X; Dong, C; Huang, J; Huang, P; Liao, R; Ren, G; Tan, Y; Wang, L; Wu, X | 1 |
| Li, M; Lu, Y; Mao, C; Wan, P; Wang, W; Yang, K; Zhang, Y; Zhu, Y | 1 |
| Alva, AS; Campagnaro, E; Qin, A; Reimers, MA; Schneider, BJ; Van Poznak, CH | 1 |
| Ang, C; Antipin, Y; Bangi, E; Bhardwaj, A; Cagan, RL; Chen, R; Donovan, M; Gruszczynski, N; Hecht, C; Kim, S; Laspina, D; Lau, CY; Malyshev, D; Misiukiewicz, K; Moe, AS; Posner, MR; Rainey, H; Schadt, EE; Sebra, R; Selkridge, I; Smibert, P; Sung, M; Taik, P; Teague, AG; Uzilov, AV; Wilck, E; Yon, WJ; Yum, K | 1 |
| Coleman, RE; Young, RJ | 1 |
| Huang, Q; Ouyang, X | 1 |
| Bernstein, M; Fan, TM; Goldsby, RE; Gorlick, R; Isakoff, MS; Kim, G; Krailo, M; Lee, S; Marina, N; Meyer, J; Randall, RL; Villaluna, D; Wagner, LM | 1 |
| Evdokiou, A; Fung, KP; Ko, CH; Lau, CB; Lee, JK; Lee, MY; Leung, PC; Li, G; Luo, KW; Shum, WT; Siu, WS; Yue, GG | 1 |
| Hahn, NM; Kirkpatrick, K; Sharma, J; Sweeney, CJ; Yiannoutsos, CT | 1 |
| Banys, M; Becker, S; Fehm, T; Gebauer, G; Hirnle, P; Huober, J; Janni, W; Kraemer, B; Krawczyk, N; Lueck, HJ; Solomayer, EF; Wackwitz, B; Wallwiener, D | 1 |
| Brown, J; Fullarton, JR; Palmieri, C | 1 |
| Abbadessa, G; Broggini, M; Chilà, R; Previdi, S; Ricci, F; Scolari, F | 1 |
| Abal, M; Aguín, S; Alonso-Alconada, L; Carmona, M; Garcia, D; López-López, R; Martínez, N; Muinelo-Romay, L; Vieito, M | 1 |
| Song, Z; Zhang, Y | 1 |
| Saad, F | 1 |
| Bajory, Z; Bouzid, M; Cathomas, R; El Ghoneimy, A; Gillessen, S; Goncalves, F; Kacso, G; Kramer, G; Lesniewski-Kmak, K; Milecki, P; Pacik, D; Tantawy, W | 1 |
| Froehner, M; Hakenberg, OW; Hölscher, T; Wirth, MP | 1 |
| Bouvet, M; Endo, I; Fleming, JB; Hiroshima, Y; Hoffman, RM; Katz, MH; Maawy, AA | 1 |
| Fan, KH; Hou, J; Hu, XY; Huang, Q; Ma, J; Ren, JD; Tan, Y; Wu, J; Xiao, JR; Xiao, WJ; Zheng, W | 1 |
| Braybrooke, JP; Clive, AO; Edey, AJ; Hall, D; Hooper, CE; Kahan, BC; Lyburn, I; Lyen, SM; Maskell, NA; Milton, T; Morley, AJ; Sequeiros, I; White, P; Zahan-Evans, N | 1 |
| Fung, KP; Gao, S; Ko, CH; Lau, CB; Lee, JK; Leung, PC; Li, G; Luo, KW; Yue, GG | 1 |
| Balakumaran, A; Body, JJ; Braun, A; Brown, J; Cleeland, C; Damyanov, D; Egerdie, B; Fallowfield, L; Marx, G; Palazzo, FS; Patrick, DL; Qian, Y; Stopeck, A; von Moos, R; Zhou, Y | 1 |
| Amiaud, J; Battaglia, S; Baud'huin, M; Heymann, D; Lamoureux, F; Ory, B; Quillard, T; Redini, F; Royer, BB; Verrecchia, F | 1 |
| Alzouebi, M; Amos, C; Attard, G; Beesley, S; Birtle, AJ; Brock, S; Cathomas, R; Chakraborti, P; Chowdhury, S; Clarke, NW; Cook, A; Cross, W; de Bono, J; Dearnaley, DP; Elliott, T; Gale, J; Gibbs, S; Graham, JD; Hetherington, J; Hughes, R; James, ND; Jones, RJ; Laing, R; Mason, MD; Matheson, D; McKinna, F; McLaren, DB; Millman, R; O'Sullivan, JM; Parikh, O; Parker, CC; Parmar, MK; Peedell, C; Protheroe, A; Ritchie, AW; Robinson, AJ; Russell, JM; Spears, MR; Srihari, N; Srinivasan, R; Staffurth, J; Sundar, S; Sydes, MR; Thalmann, G; Tolan, S; Tsang, D; Wagstaff, J | 1 |
| Alexeeva, Y; Balakumaran, A; Braun, A; Facon, T; Feng, A; Hungria, V; Raje, N; Roodman, GD; Spencer, A; Stewart, AK; Terpos, E; Vadhan-Raj, S; Willenbacher, W | 1 |
| Chiarugi, P; Comito, G; Giannoni, E; Lanciotti, M; Morandi, A; Pons Segura, C; Serni, S; Taddei, ML | 1 |
| Byrum, ML; Fan, TM; Fredrickson, RL; Pondenis, HC; Wycislo, KL | 1 |
| Alho, I; Ali, S; Casimiro, S; Costa, L; Faria, M; Ferreira, AR; Leitzel, K; Lipton, A; Matias, M; Shan, N | 1 |
| Anderson, J; Clarke, NW; Dearnaley, DP; Dwyer, J; James, ND; Mason, MD; Masters, J; Morgan, RC; Parmar, MK; Popert, RJ; Sanders, K; Stansfeld, J; Sydes, MR | 2 |
| Arita, K; Hiranuma, S; Kuramochi, J; Kurokawa, T; Matsumoto, A; Sanada, K; Takiguchi, N; Tanaka, Y; Usui, S | 1 |
| Nakagawa, K; Okamoto, I; Okamoto, K; Terashima, M; Tsurutani, J | 1 |
| Amir, E; Clemons, M; Fralick, M; Freedman, OC; Hardisty, M; Kumar, R; Whyne, C | 1 |
| Ikeda, T; Nagamine, I; Ohara, M; Okada, M; Yamaguchi, Y | 1 |
| Apicelli, AJ; Becker, SN; Deng, H; Eagleton, MC; Floyd, DH; Hirbe, AC; Lanigan, LG; Piwnica-Worms, D; Prior, JL; Roelofs, AJ; Rogers, MJ; Weilbaecher, K; Xu, Z | 1 |
| Linneman, T; McMahan, J | 1 |
| Alexandre, J; Bertagna, X; Boudou-Rouquette, P; Goldwasser, F; Soubrane, O | 1 |
| Alkan, A; Altundag, K; Sahin, U | 1 |
| Baziotis, N; Limouris, GS; Zafeirakis, A; Zissimopoulos, A | 1 |
| Hirsh, V; Langer, C | 1 |
| Clézardin, P | 1 |
| Fujimoto, Y; Manabe, J; Orita, Y; Sugitani, I; Toda, K | 1 |
| Chan, J; Hung, TT; Power, CA; Russell, PJ | 1 |
| Lockhart, AC; Sorscher, SM | 1 |
| Calderone, R; Leary, A; Nimako, K; O'Brien, ME; Popat, S | 1 |
| Frustino, JL; Kossoff, EB; Ngamphaiboon, N; O'Connor, TL; Sullivan, MA | 1 |
| Hagi, T; Mattarollo, SR; Nicol, AJ; Nieda, M; Suzuki, K; Tokuyama, H; Yokokawa, K | 1 |
| Brown, HK; Brown, NJ; Coleman, RE; Cross, SS; Holen, I; Jones, M; Ottewell, PD; Rogers, TL | 1 |
| Kumar, A; Manjappa, AS; Megraj Khandelwal, VK; Mishra, AK; Monkkonen, J; Ramachandra Murthy, RS; Ramanlal Chaudhari, K; Ukawala, M | 1 |
| Body, JJ | 1 |
| Bundred, N | 1 |
| Abdelkarim, M; Crepin, M; Di Benedetto, M; Jais, JP; Kassis, N; Lecouvey, M; Perret, GY; Vintonenko, N | 1 |
| Coleman, R; Gnant, M; Green, J; Hadji, P | 1 |
| Coleman, RE | 1 |
| Feng, JY; Wang, SJ; Wu, CQ; Zhang, P; Zheng, XH | 1 |
| Dedes, PG; Gialeli, Ch; Kanakis, I; Karamanos, NK; Kletsas, D; Theocharis, AD; Tsegenidis, T; Tzanakakis, GN | 1 |
| Brown, LG; Corey, E; Higano, CS; Poot, M; Quinn, JE; Roudier, MP; Vessella, RL | 1 |
| Denoyelle, C; Hong, L; Soria, C; Soria, J; Vannier, JP | 1 |
| Booth, B; Chen, G; Gobburu, JV; Hsieh, Y; Ibrahim, A; Leighton, J; Li, N; Pazdur, R; Rahman, A; Scher, N; Sridhara, R; Vause, D; Williams, G; Wood, R | 1 |
| Altomare, V; Avvisati, G; Battistoni, F; Bonsignori, M; Dicuonzo, G; Gavasci, M; Massacesi, C; Rocci, L; Santini, D; Tirindelli, MC; Tocchini, M; Tonini, G; Vincenzi, B | 1 |
| Baldi, A; Santini, D; Scarpa, S; Tonini, G; Vincenzi, B | 1 |
| Bartsch, R; Hussian, D; Locker, GJ; Pluschnig, U; Sevelda, U; Steger, GG; Wenzel, C; Zielinski, CC | 1 |
| Hiraga, T; Tamura, D; Ueda, A; Williams, PJ; Yoneda, T | 1 |
| Brown, MD; Clarke, NW; George, NJ; Hart, CA; Montague, R; Ramani, VA | 1 |
| Bukowski, RM; Colombo-Berra, A; Lipton, A; Rosen, L; Urbanowitz, G; Zheng, M | 1 |
| Barrett-Lee, P; Body, JJ; Canney, P; De Cock, E; Hutton, J; Lewis, G; Neary, MP | 1 |
| Blanchard, F; Charrier, C; Coipeau, P; Couillaud, S; Gouin, F; Heymann, D; Heymann, MF; Ory, B; Redini, F; Thiery, JP | 1 |
| Brown, LG; Corey, E; Keller, ET; Quinn, JE; Vessella, RL; Zhang, J | 1 |
| Dunleavy, R; Liauw, W; Lih, A; Links, M; Segelov, E; Ward, R | 1 |
| Barutca, S; Erdogan, S; Koseoglu, K; Meydan, N; Yurekli, Y | 1 |
| Nagy, Z | 1 |
| Klain, M; Liuzzi, R; Marinelli, A; Molino, L; Pace, L; Paone, G; Salvatore, M; Soricelli, A; Storto, G | 1 |
| Do, KA; Jonasch, E; Lin, P; Lin, SH; Mathew, P; Pagliaro, LC; Rhines, L; Siefker-Radtke, A; Tannir, N; Tibbs, R; Tu, SM | 1 |
| Kantoff, P; Kaufman, DS; Michaelson, MD; Oh, WK; Smith, MR | 1 |
| Anstrom, KJ; Castel, LD; DePuy, V; Saad, F; Schulman, KA; Weinfurt, KP | 1 |
| Altieri, V; Autorino, R; Cancello, G; D'Armiento, M; De Laurentiis, M; De Placido, S; Di Lorenzo, G; Figg, WD; Imbimbo, C; Longo, N; Mirone, V; Perdonà, S; Tortora, G | 1 |
| Eagleton, MC; Hirbe, AC; Morgan, EA; Piwnica-Worms, D; Prior, JL; Rubin, J; Uluçkan, O; Weilbaecher, KN | 1 |
| Dahmane, A; de Klerk, JM; Lam, MG; Stevens, WH; van Rijk, PP; Zonnenberg, BA | 1 |
| Boissier, S; Clézardin, P; Colombel, M; Delaissé, JM; Delmas, P; Ebetino, FH; Ferreras, M; Magnetto, S; Peyruchaud, O | 1 |
| Berenson, JR; Givant, E; Harvey, H; Hupkes, M; Lipton, A; Rosen, LS; Savage, A; Swift, R; Vescio, RA; VonTeichert, JM; Woo, M | 1 |
| Hiraga, T; Mundy, GR; Yoneda, T | 1 |
14 review(s) available for zoledronic acid and Metastase
| Article | Year |
|---|---|
Use of Bone-Modifying Agents in Myeloma and Bone Metastases: How Recent Dosing Interval Studies Have Affected Our Practice.
Topics: Bone Density Conservation Agents; Humans; Neoplasm Metastasis; Practice Patterns, Physicians'; Zoledronic Acid | 2018 |
Bone markers for monitoring efficacy in patients
with bone metastases receiving zoledronic acid:
a review of published data.
Topics: Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Neoplasm Metastasis; Zoledronic Acid | 2013 |
Comparative efficacy of bisphosphonates in metastatic breast and prostate cancer and multiple myeloma: a mixed-treatment meta-analysis.
Topics: Breast Neoplasms; Clodronic Acid; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Male; Multiple Myeloma; Neoplasm Metastasis; Pamidronate; Prostatic Neoplasms; Zoledronic Acid | 2013 |
Management of bone metastases in patients with castration-resistant prostate cancer.
Topics: Antibodies, Monoclonal, Humanized; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Humans; Imidazoles; Interdisciplinary Communication; Male; Medical Oncology; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Spinal Cord Compression; Treatment Outcome; Zoledronic Acid | 2014 |
Treatment of bone metastases in urologic malignancies.
Topics: Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Cisplatin; Denosumab; Diphosphonates; Humans; Imidazoles; Male; Neoplasm Metastasis; Neoplasms, Germ Cell and Embryonal; Prostatic Neoplasms; Quality of Life; Radiosurgery; Treatment Outcome; Urinary Bladder Neoplasms; Urologic Neoplasms; Zoledronic Acid | 2014 |
Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Survival Results From STAMPEDE (NCT00268476).
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Density Conservation Agents; Celecoxib; Clinical Trials as Topic; Cyclooxygenase 2 Inhibitors; Diphosphonates; Humans; Imidazoles; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prostatic Neoplasms; Retreatment; Treatment Outcome; Zoledronic Acid | 2016 |
Skeletal morbidity in lung cancer patients with bone metastases: demonstrating the need for early diagnosis and treatment with bisphosphonates.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Diphosphonates; Humans; Imidazoles; Incidence; Lung Neoplasms; Neoplasm Metastasis; Zoledronic Acid | 2010 |
[Antitumor properties of the bisphosphonate zoledronate and potential therapeutic implications in the clinic].
Topics: Animals; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Neoplasm Metastasis; Neoplasms; Zoledronic Acid | 2010 |
Denosumab for the management of bone disease in patients with solid tumors.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biological Availability; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodeling; Clinical Trials as Topic; Denosumab; Diphosphonates; Disease Management; Humans; Imidazoles; Immunologic Factors; Neoplasm Metastasis; Neoplasms; Outcome Assessment, Health Care; Palliative Care; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Zoledronic Acid | 2012 |
Antiresorptive therapies in oncology and their effects on cancer progression.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone and Bones; Bone Density Conservation Agents; Controlled Clinical Trials as Topic; Denosumab; Diphosphonates; Disease Progression; Humans; Imidazoles; Neoplasm Metastasis; Neoplasms; RANK Ligand; Zoledronic Acid | 2012 |
The impact of menopause on bone, zoledronic acid, and implications for breast cancer growth and metastasis.
Topics: Antineoplastic Agents; Bone Density; Bone Density Conservation Agents; Bone Marrow; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Menopause; Neoplasm Metastasis; Zoledronic Acid | 2012 |
Adjuvant bone-targeted therapy to prevent metastasis: lessons from the AZURE study.
Topics: Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Male; Neoplasm Metastasis; Prostatic Neoplasms; Women's Health; Zoledronic Acid | 2012 |
Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid.
Topics: Bone Diseases; Bone Neoplasms; Bone Resorption; Carcinoma, Renal Cell; Diphosphonates; Humans; Imidazoles; Kidney Neoplasms; Neoplasm Metastasis; Osteolysis; Zoledronic Acid | 2004 |
Preclinical studies with zoledronic acid and other bisphosphonates: impact on the bone microenvironment.
Topics: Animals; Bone and Bones; Bone Neoplasms; Diphosphonates; Drug Evaluation, Preclinical; Imidazoles; Mammary Neoplasms, Experimental; Mice; Models, Animal; Neoplasm Metastasis; Rats; Zoledronic Acid | 2001 |
18 trial(s) available for zoledronic acid and Metastase
| Article | Year |
|---|---|
Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307.
Topics: Administration, Oral; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Clodronic Acid; Diphosphonates; Disease-Free Survival; Female; Humans; Ibandronic Acid; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Survival Rate; Treatment Outcome; Zoledronic Acid | 2020 |
Feasibility and dose discovery analysis of zoledronic acid with concurrent chemotherapy in the treatment of newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Edema; Extremities; Feasibility Studies; Female; Humans; Hypokalemia; Hyponatremia; Hypophosphatemia; Imidazoles; Kaplan-Meier Estimate; Male; Mucositis; Neoplasm Metastasis; Osteosarcoma; Pain; Treatment Outcome; Young Adult; Zoledronic Acid | 2013 |
Failure to suppress markers of bone turnover on first-line hormone therapy for metastatic prostate cancer is associated with shorter time to skeletal-related event.
Topics: Aged; Alkaline Phosphatase; Amino Acids; Androgen Antagonists; Antibodies, Monoclonal, Humanized; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Remodeling; Denosumab; Diphosphonates; Disease Progression; Disease-Free Survival; Humans; Imidazoles; Male; Middle Aged; Neoplasm Metastasis; Orchiectomy; Osteocalcin; Pamidronate; Prognosis; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Zoledronic Acid | 2014 |
Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: results of a prospective clinical trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Marrow; Breast Neoplasms; Chemoradiotherapy, Adjuvant; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Time Factors; Tumor Burden; Zoledronic Acid | 2013 |
Zoledronic Acid may reduce intraoperative bleeding in spinal tumors: a prospective cohort study.
Topics: Adult; Aged; Blood Loss, Surgical; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Neoplasm Metastasis; Spinal Neoplasms; Zoledronic Acid | 2015 |
A randomised controlled trial of intravenous zoledronic acid in malignant pleural disease: a proof of principle pilot study.
Topics: Administration, Intravenous; Aged; Biomarkers; Diphosphonates; Dyspnea; Female; Humans; Imidazoles; Male; Neoplasm Metastasis; Pilot Projects; Pleura; Pleural Effusion, Malignant; Quality of Life; Safety; Treatment Outcome; Zoledronic Acid | 2015 |
Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases.
Topics: Analgesics; Bone Neoplasms; Denosumab; Diphosphonates; Double-Blind Method; Female; Fractures, Spontaneous; Humans; Imidazoles; Male; Middle Aged; Neoplasm Metastasis; Pain; Zoledronic Acid | 2016 |
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Diphosphonates; Disease Progression; Docetaxel; Drug Administration Schedule; Humans; Imidazoles; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms; Taxoids; Treatment Outcome; Zoledronic Acid | 2016 |
Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Female; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Neoplasm Metastasis; Neoplasm Staging; Neoplasms; Transplantation, Autologous; Treatment Outcome; Zoledronic Acid | 2016 |
Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi-arm, multistage randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Diphosphonates; Docetaxel; Humans; Imidazoles; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms; Pyrazoles; Risk Factors; Sulfonamides; Taxoids; Treatment Outcome; Zoledronic Acid | 2009 |
Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours.
Topics: Aged; Diphosphonates; Feasibility Studies; Female; Humans; Imidazoles; Immunotherapy, Adoptive; Lymphocyte Activation; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocyte Subsets; T-Lymphocytes; Treatment Outcome; Zoledronic Acid | 2011 |
[Efficacy of 153Sm-EDTMP in the treatment of prostate cancer with bone metastasis].
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Male; Middle Aged; Neoplasm Metastasis; Organometallic Compounds; Organophosphorus Compounds; Prostatic Neoplasms; Zoledronic Acid | 2012 |
Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.
Topics: Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; Diphosphonates; Dose-Response Relationship, Drug; Female; Humans; Imidazoles; Kidney; Male; Multiple Myeloma; Neoplasm Metastasis; Placebos; Prostatic Neoplasms; Time Factors; United States; United States Food and Drug Administration; Zoledronic Acid | 2003 |
Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid.
Topics: Bone Diseases; Bone Neoplasms; Bone Resorption; Carcinoma, Renal Cell; Diphosphonates; Humans; Imidazoles; Kidney Neoplasms; Neoplasm Metastasis; Osteolysis; Zoledronic Acid | 2004 |
Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-gamma for metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Female; Humans; Imidazoles; Interferon-gamma; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pilot Projects; Thalidomide; Zoledronic Acid | 2006 |
Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Biomarkers, Tumor; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Disease Progression; Dyspnea; Edema; Humans; Imidazoles; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms; Pyrrolidines; Treatment Outcome; Zoledronic Acid | 2006 |
Docetaxel, vinorelbine, and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: a phase II study.
Topics: Adenocarcinoma; Aged; Biomarkers, Tumor; Bone Neoplasms; Diphosphonates; Docetaxel; Humans; Imidazoles; Male; Middle Aged; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Survivors; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine; Zoledronic Acid | 2007 |
A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases.
Topics: Adult; Aged; Bone Neoplasms; Bone Resorption; Creatinine; Diphosphonates; Dose-Response Relationship, Drug; Female; Humans; Imidazoles; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Time Factors; Zoledronic Acid | 2001 |
61 other study(ies) available for zoledronic acid and Metastase
| Article | Year |
|---|---|
Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Denosumab; Drug Synergism; Female; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Lymphocytes; Male; Middle Aged; Neoplasm Metastasis; Neutrophils; Prognosis; Retrospective Studies; Survival Analysis; Zoledronic Acid | 2021 |
Treatment options for patients with prostate cancer who develop metastatic disease after hormonal therapy.
Topics: Abiraterone Acetate; Absorptiometry, Photon; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Docetaxel; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prednisolone; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Zoledronic Acid | 2019 |
Bisphosphonates as a therapeutic choice for multifocal epithelioid hemangioma of bone: A case report.
Topics: Biopsy; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodeling; Combined Modality Therapy; Diagnosis, Differential; Diphosphonates; Drug Monitoring; Hemangioendothelioma, Epithelioid; Humans; Immunohistochemistry; Male; Middle Aged; Neoplasm Metastasis; Orthopedic Procedures; Treatment Outcome; Zoledronic Acid | 2019 |
Radiation therapy combined with bone-modifying agents ameliorates local control of osteolytic bone metastases in breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Combined Modality Therapy; Denosumab; Female; Humans; Middle Aged; Neoplasm Metastasis; Osteolysis; Pamidronate; Prognosis; Radiotherapy, Conformal; Retrospective Studies; Spine; Zoledronic Acid | 2020 |
A case of delayed-onset scarring alopecia in a 75-year-old woman.
Topics: Aged; Alopecia; Anastrozole; Aromatase Inhibitors; Biopsy; Bone Density Conservation Agents; Breast Neoplasms; Cicatrix; Diagnosis, Differential; Drug Therapy, Combination; Erythema; Female; Humans; Immunohistochemistry; Neoplasm Metastasis; Piperazines; Protein Kinase Inhibitors; Pyridines; Scalp; Telangiectasis; Zoledronic Acid | 2020 |
Synergistic effect of graphene oxide and zoledronic acid for osteoporosis and cancer treatment.
Topics: Breast Neoplasms; Cell Differentiation; Cell Proliferation; Cell Survival; Female; Graphite; Humans; MCF-7 Cells; Nanostructures; Neoplasm Metastasis; Osteoporosis; Zoledronic Acid | 2020 |
Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Density Conservation Agents; Bone Neoplasms; Chemoradiotherapy; Clinical Trials, Phase III as Topic; Denosumab; Humans; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms, Castration-Resistant; Radium; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Rate; Treatment Outcome; Zoledronic Acid | 2020 |
Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases.
Topics: Aged; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Humans; Male; Neoplasm Metastasis; Retrospective Studies; Treatment Outcome; Zoledronic Acid | 2021 |
Acute Bilateral Anterior Uveitis after a Single Intravenous Infusion of Zoledronic Acid in Metastatic Breast Cancer.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Uveitis, Anterior; Zoledronic Acid | 2017 |
Inhibition of UGT8 suppresses basal-like breast cancer progression by attenuating sulfatide-αVβ5 axis.
Topics: Animals; Biosynthetic Pathways; Breast Neoplasms; Carcinogenesis; Cell Line, Tumor; Cell Movement; Disease Progression; Female; Ganglioside Galactosyltransferase; Gene Expression Regulation, Neoplastic; Humans; Mice, SCID; Neoplasm Invasiveness; Neoplasm Metastasis; Receptors, Vitronectin; Signal Transduction; SOXE Transcription Factors; Sulfoglycosphingolipids; Survival Analysis; Up-Regulation; Zoledronic Acid | 2018 |
Molecular and cellular mechanisms for zoledronic acid-loaded magnesium-strontium alloys to inhibit giant cell tumors of bone.
Topics: Alloys; Apoptosis; Biocompatible Materials; Bone and Bones; Bone Neoplasms; Calcium Phosphates; Cell Movement; Cytoskeleton; Diphosphonates; Giant Cell Tumor of Bone; Humans; Magnesium; Mitochondria; Neoplasm Metastasis; Neoplasms; NF-kappa B; Osteoclasts; Osteolysis; Oxidative Stress; Recurrence; Risk Factors; Signal Transduction; Strontium; Zoledronic Acid | 2018 |
A personalized platform identifies trametinib plus zoledronate for a patient with KRAS-mutant metastatic colorectal cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Progression; Drosophila; Drug Administration Schedule; Drug Screening Assays, Antitumor; Female; Genes, ras; Genomics; Humans; Male; Middle Aged; Mutation; Neoplasm Metastasis; Precision Medicine; Pyridones; Pyrimidinones; Zoledronic Acid | 2019 |
Zoledronic acid to prevent and treat cancer metastasis: new prospects for an old drug.
Topics: Antineoplastic Agents; Bone Neoplasms; Cell Transformation, Neoplastic; Clinical Trials, Phase III as Topic; Diphosphonates; Humans; Imidazoles; Metabolic Networks and Pathways; Neoplasm Metastasis; Neoplasms; Zoledronic Acid | 2013 |
Anti-tumor and anti-osteolysis effects of the metronomic use of zoledronic acid in primary and metastatic breast cancer mouse models.
Topics: Administration, Metronomic; Animals; Antineoplastic Agents; Bone and Bones; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Mammary Neoplasms, Experimental; Mice; Neoplasm Metastasis; Osteolysis; Radiography; Tumor Burden; Zoledronic Acid | 2013 |
Combination of the c-Met inhibitor tivantinib and zoledronic acid prevents tumor bone engraftment and inhibits progression of established bone metastases in a breast xenograft model.
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Diphosphonates; Female; Heterografts; Humans; Imidazoles; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinolines; X-Ray Microtomography; Zoledronic Acid | 2013 |
Zoledronic acid as an antimetastatic agent for different human tumor cell lines.
Topics: Cell Line, Tumor; Diphosphonates; Humans; Imidazoles; Neoplasm Invasiveness; Neoplasm Metastasis; Zoledronic Acid | 2013 |
Zoledronic acid treatment in advanced non-small cell lung cancer patients with bone metastases.
Topics: Aged; Antineoplastic Agents; Apoptosis; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Diphosphonates; Drug Administration Schedule; Female; Humans; Imidazoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pleural Effusion, Malignant; Tomography, X-Ray Computed; Treatment Outcome; Zoledronic Acid | 2014 |
Prostate cancer: preventing metastasis to bone: is this the end of the story?
Topics: Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Male; Neoplasm Metastasis; Prostatic Neoplasms; Treatment Failure; Zoledronic Acid | 2014 |
Selective efficacy of zoledronic acid on metastasis in a patient-derived orthotopic xenograph (PDOX) nude-mouse model of human pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Deoxycytidine; Diphosphonates; Gemcitabine; Humans; Imidazoles; Immunoenzyme Techniques; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Neoplasm Metastasis; Pancreatic Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; Zoledronic Acid | 2015 |
The combined use of Camellia sinensis and metronomic zoledronate in 4T1 mouse carcinoma against tumor growth and metastasis.
Topics: Administration, Metronomic; Animals; Camellia sinensis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Diphosphonates; Drug Therapy, Combination; Female; Gene Expression Regulation, Neoplastic; Imidazoles; Mammary Neoplasms, Experimental; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Neoplasm Metastasis; Osteolysis; Plant Extracts; Zoledronic Acid | 2015 |
Blocking HSP90 Addiction Inhibits Tumor Cell Proliferation, Metastasis Development, and Synergistically Acts with Zoledronic Acid to Delay Osteosarcoma Progression.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Disease Progression; Drug Synergism; Female; HSP90 Heat-Shock Proteins; Humans; Imidazoles; Mice; Mice, Nude; Monocytes; Neoplasm Metastasis; Osteosarcoma; Signal Transduction; Xenograft Model Antitumor Assays; Zoledronic Acid | 2016 |
Zoledronic acid impairs stromal reactivity by inhibiting M2-macrophages polarization and prostate cancer-associated fibroblasts.
Topics: Cancer-Associated Fibroblasts; Cell Line, Tumor; Cell Movement; Diphosphonates; Humans; Imidazoles; Macrophage Activation; Macrophages; Male; Mevalonic Acid; Neoplasm Metastasis; Neovascularization, Pathologic; Phenotype; Prostatic Neoplasms; rhoA GTP-Binding Protein; Stromal Cells; Tumor Microenvironment; Zoledronic Acid | 2017 |
Downregulation of CXCR4 Expression and Functionality After Zoledronate Exposure in Canine Osteosarcoma.
Topics: Animals; Bone Neoplasms; Cell Line, Tumor; Diphosphonates; Dog Diseases; Dogs; Female; Gene Expression Regulation, Neoplastic; Imidazoles; Male; Neoplasm Metastasis; Osteosarcoma; Receptors, CXCR4; Zoledronic Acid | 2016 |
N-Telopeptide of Type I Collagen Long-Term Dynamics in Breast Cancer Patients With Bone Metastases: Clinical Outcomes and Influence of Extraskeletal Metastases.
Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Collagen Type I; Diphosphonates; Female; Humans; Imidazoles; Middle Aged; Neoplasm Metastasis; Peptides; Prognosis; Prospective Studies; Receptors, Estrogen; Zoledronic Acid | 2016 |
STAMPEDE: Systemic Therapy for Advancing or Metastatic Prostate Cancer--a multi-arm multi-stage randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Diphosphonates; Docetaxel; Humans; Imidazoles; Male; Neoplasm Metastasis; Pilot Projects; Prostatic Neoplasms; Pyrazoles; Randomized Controlled Trials as Topic; Sulfonamides; Taxoids; Zoledronic Acid | 2008 |
[A case of recurrent breast carcinoma metastasis successfully treated with S-1 and zoledronic acid therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Diphosphonates; Drug Combinations; Female; Humans; Imidazoles; Magnetic Resonance Imaging; Neoplasm Metastasis; Oxonic Acid; Recurrence; Tegafur; Tomography, X-Ray Computed; Treatment Outcome; Zoledronic Acid | 2009 |
Zoledronic acid-induced regression of multiple metastases at nonskeletal sites.
Topics: Aged; Diphosphonates; Humans; Imidazoles; Male; Neoplasm Metastasis; Positron-Emission Tomography; Zoledronic Acid | 2009 |
Radiological changes following second-line zoledronic acid treatment in breast cancer patients with bone metastases.
Topics: Adult; Bone and Bones; Bone Density; Bone Neoplasms; Breast Neoplasms; Cohort Studies; Diphosphonates; Female; Humans; Imidazoles; Medical Oncology; Middle Aged; Neoplasm Metastasis; Osteoblasts; Tomography, X-Ray Computed; Zoledronic Acid | 2009 |
Induction of gamma delta T cells using zoledronate plus interleukin-2 in patients with metastatic cancer.
Topics: Antineoplastic Agents; Case-Control Studies; Cell Line, Tumor; Cell Membrane; Cell Proliferation; Colorectal Neoplasms; Diphosphonates; Esophageal Neoplasms; Humans; Imidazoles; Immunotherapy, Adoptive; Interleukin-2; Leukocytes, Mononuclear; Lymphocyte Activation; Neoplasm Metastasis; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocytes; Zoledronic Acid | 2009 |
The bisphosphonate zoledronic acid decreases tumor growth in bone in mice with defective osteoclasts.
Topics: Animals; Bone Neoplasms; Cell Line, Tumor; Cell Survival; Diphosphonates; Enzyme Activation; Geranyltranstransferase; Imidazoles; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neoplasm Metastasis; Osteoclasts; Protein Prenylation; Zoledronic Acid | 2009 |
A case of resistant hypercalcemia of malignancy with a proposed treatment algorithm.
Topics: Aged; Algorithms; Bone Density Conservation Agents; Calcitonin; Carcinoma, Transitional Cell; Crystalloid Solutions; Diphosphonates; Humans; Hypercalcemia; Imidazoles; Isotonic Solutions; Male; Neoplasm Metastasis; Pamidronate; Ureteral Neoplasms; Zoledronic Acid | 2009 |
Antitumoral effect of the bisphosphonate zoledronic acid against visceral metastases in an adrenocortical cancer patient.
Topics: Adrenal Cortex Neoplasms; Adult; Antineoplastic Agents; Diphosphonates; Humans; Imidazoles; Male; Neoplasm Metastasis; Radiography; Treatment Outcome; Zoledronic Acid | 2009 |
Bone morphogenetic proteins and zoledronic acid.
Topics: Adrenal Cortex Neoplasms; Bone Density Conservation Agents; Bone Morphogenetic Proteins; Diphosphonates; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Neoplasm Metastasis; Zoledronic Acid | 2009 |
Management of metastatic bone pain with repeated doses of rhenium 186-HEDP in patients under therapy with zoledronic acid: a safe and additively effective practice.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Etidronic Acid; Female; Humans; Imidazoles; Male; Middle Aged; Neoplasm Metastasis; Organometallic Compounds; Pain; Pain Measurement; Prostatic Neoplasms; Treatment Outcome; Zoledronic Acid | 2009 |
Zoledronic acid in the treatment of bone metastases from differentiated thyroid carcinoma.
Topics: Adult; Aged; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Male; Middle Aged; Neoplasm Metastasis; Osteoclasts; Thyroid Neoplasms; Treatment Outcome; Zoledronic Acid | 2011 |
Zoledronic acid preserves bone structure and increases survival but does not limit tumour incidence in a prostate cancer bone metastasis model.
Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Imidazoles; Incidence; Male; Mice; Neoplasm Metastasis; Prostatic Neoplasms; Survival Rate; Zoledronic Acid | 2011 |
Ras inhibition and the survival benefit favoring zoledronic acid compared with denosumab in patients with multiple myeloma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biopsy; Bone Neoplasms; Denosumab; Diphosphonates; Humans; Imidazoles; Multiple Myeloma; Neoplasm Metastasis; Neoplasms; Protein Processing, Post-Translational; Randomized Controlled Trials as Topic; RANK Ligand; ras Proteins; Treatment Outcome; Zoledronic Acid | 2011 |
Under usage of zoledronic acid in non-small cell lung cancer patients with metastatic bone disease--a short communication.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Diphosphonates; Drug Therapy, Combination; Female; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Retrospective Studies; Treatment Outcome; Zoledronic Acid | 2011 |
Osteonecrosis of the jaw: dental outcomes in metastatic breast cancer patients treated with bisphosphonates with/without bevacizumab.
Topics: Adult; Aged; Angiogenesis Inhibitors; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Jaw Diseases; Middle Aged; Neoplasm Metastasis; Osteonecrosis; Pamidronate; Retrospective Studies; Survival Rate; Treatment Outcome; Zoledronic Acid | 2011 |
Combination therapy inhibits development and progression of mammary tumours in immunocompetent mice.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Density Conservation Agents; Cell Proliferation; Diphosphonates; Disease Models, Animal; Disease Progression; Doxorubicin; Female; Imidazoles; Immunocompetence; Macrophages; Male; Mammary Neoplasms, Experimental; Mice; Neoplasm Metastasis; Neoplasm Staging; Neovascularization, Pathologic; Zoledronic Acid | 2012 |
Bone metastasis targeting: a novel approach to reach bone using Zoledronate anchored PLGA nanoparticle as carrier system loaded with Docetaxel.
Topics: Animals; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Cell Line; Cell Line, Tumor; Diphosphonates; Docetaxel; Drug Carriers; Humans; Imidazoles; Lactic Acid; Mice; Nanoparticles; Neoplasm Metastasis; Polyethylene Glycols; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Taxoids; Zoledronic Acid | 2012 |
Transcriptome analysis and in vivo activity of fluvastatin versus zoledronic acid in a murine breast cancer metastasis model.
Topics: Adenocarcinoma; Animals; Breast Neoplasms; Cell Line, Tumor; Diphosphonates; Disease Models, Animal; Disease Progression; Fatty Acids, Monounsaturated; Female; Fluvastatin; Gene Expression; Gene Expression Profiling; Humans; Imidazoles; Indoles; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Neoplasm Metastasis; Transcriptome; Zoledronic Acid | 2012 |
Preclinical evaluation of zoledronate using an in vitro mimetic cellular model for breast cancer metastatic bone disease.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cathepsin K; Cell Line, Tumor; Coculture Techniques; Collagen Type I; Diphosphonates; Drug Screening Assays, Antitumor; Female; Humans; Imidazoles; Integrin beta3; Macrophage Colony-Stimulating Factor; Models, Biological; Neoplasm Metastasis; Osteoclasts; Osteolysis; RANK Ligand; Zoledronic Acid | 2013 |
Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Neoplasms; Cathepsin K; Cathepsins; Cell Division; Diphosphonates; Humans; Imidazoles; Immunohistochemistry; In Situ Nick-End Labeling; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Mice, Inbred BALB C; Neoplasm Metastasis; Neoplasm Transplantation; Osteoblasts; Prostatic Neoplasms; Time Factors; Tumor Cells, Cultured; Zoledronic Acid | 2003 |
New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects.
Topics: Bone Resorption; Breast Neoplasms; Cell Movement; Chemokine CXCL12; Chemokines, CXC; Cyclooxygenase 2; Dinoprostone; Diphosphonates; Dose-Response Relationship, Drug; Female; Gene Expression Regulation; Humans; Imidazoles; Isoenzymes; Membrane Proteins; Neoplasm Invasiveness; Neoplasm Metastasis; Osteolysis; Prostaglandin-Endoperoxide Synthases; rhoA GTP-Binding Protein; Tumor Cells, Cultured; Zoledronic Acid | 2003 |
Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Angiogenic Proteins; Bone Neoplasms; Cytokines; Diphosphonates; Dose-Response Relationship, Drug; Female; Humans; Imidazoles; Male; Middle Aged; Neoplasm Metastasis; Platelet-Derived Growth Factor; Time Factors; Vascular Endothelial Growth Factor A; Zoledronic Acid | 2003 |
Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer.
Topics: Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Male; Neoplasm Metastasis; Osteoblasts; Prostatic Neoplasms; Time Factors; Zoledronic Acid | 2003 |
Zoledronate in a patient with pamidronate refractory hypercalcemia syndrome.
Topics: Bone Resorption; Breast Neoplasms; Diphosphonates; Drug Resistance; Female; Humans; Hypercalcemia; Imidazoles; Liver Neoplasms; Middle Aged; Neoplasm Metastasis; Pamidronate; Quality of Life; Recurrence; Zoledronic Acid | 2004 |
Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model.
Topics: Animals; Apoptosis; Blotting, Western; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Separation; Cell Survival; Diphosphonates; Disease Models, Animal; Diterpenes; Dose-Response Relationship, Drug; Female; Flow Cytometry; Humans; Imidazoles; Luciferases; Lung Neoplasms; Mammary Neoplasms, Animal; Mice; Mice, Inbred BALB C; Microscopy, Fluorescence; Neoplasm Invasiveness; Neoplasm Metastasis; Osteoclasts; Time Factors; Zoledronic Acid | 2004 |
Differential inhibition of invasion and proliferation by bisphosphonates: anti-metastatic potential of Zoledronic acid in prostate cancer.
Topics: Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Diphosphonates; Epithelial Cells; Humans; Imidazoles; Male; Matrix Metalloproteinases; Neoplasm Invasiveness; Neoplasm Metastasis; Prostatic Neoplasms; Zoledronic Acid | 2004 |
Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy.
Topics: Administration, Oral; Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; Cohort Studies; Cost-Benefit Analysis; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Neoplasm Metastasis; Pamidronate; Quality of Life; State Medicine; United Kingdom; Zoledronic Acid | 2005 |
Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Remodeling; Caspases; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Fibrosis; Ifosfamide; Imidazoles; Male; Necrosis; Neoplasm Metastasis; Neoplasm Recurrence, Local; Osteoblasts; Osteogenesis; Osteosarcoma; Rats; Rats, Sprague-Dawley; S Phase; Survival Rate; Tibia; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Zoledronic Acid | 2005 |
Comparison of Fc-osteoprotegerin and zoledronic acid activities suggests that zoledronic acid inhibits prostate cancer in bone by indirect mechanisms.
Topics: Animals; Antibodies; Antineoplastic Agents; Apoptosis; Bone Density; Bone Density Conservation Agents; Bone Neoplasms; Cell Proliferation; Densitometry; Diphosphonates; Glycoproteins; Humans; Imidazoles; Immunoglobulin Fc Fragments; In Vitro Techniques; Male; Mice; Mice, SCID; Neoplasm Metastasis; Osteoclasts; Osteolysis; Osteoprotegerin; Prostatic Neoplasms; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Tibia; Time Factors; Zoledronic Acid | 2005 |
Off-trial evaluation of bisphosphonates in patients with metastatic breast cancer.
Topics: Aged; Bone Diseases; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Disease Progression; Humans; Imidazoles; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Pamidronate; Retrospective Studies; Time Factors; Treatment Outcome; Zoledronic Acid | 2005 |
Reversible metastatic visceral calcification detected by 99mTc-methylene diphosphonate bone scanning in breast cancer.
Topics: Antineoplastic Agents; Bone and Bones; Breast Neoplasms; Calcification, Physiologic; Calcium; Diphosphonates; Female; Heart Neoplasms; Humans; Imidazoles; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Stomach Neoplasms; Technetium Tc 99m Medronate; Thyroid Neoplasms; Time Factors; Zoledronic Acid | 2005 |
Zoledronic acid(ZOMETA): a significant improvement in the bone metastases.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Clinical Trials as Topic; Diphosphonates; Humans; Imidazoles; Neoplasm Metastasis; Zoledronic Acid | 2005 |
Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases.
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Combined Modality Therapy; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Male; Middle Aged; Neoplasm Metastasis; Pain; Palliative Care; Prostatic Neoplasms; Strontium Radioisotopes; Time Factors; Treatment Outcome; Zoledronic Acid | 2006 |
Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer.
Topics: Aged; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Male; Musculoskeletal System; Neoplasm Metastasis; Prognosis; Prostatic Neoplasms; Quality of Life; Risk Factors; Survival; Treatment Outcome; Zoledronic Acid | 2007 |
Disruption of CXCR4 enhances osteoclastogenesis and tumor growth in bone.
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Cell Division; Diphosphonates; Imidazoles; Kinetics; Macrophages; Mice; Mice, Knockout; Neoplasm Metastasis; Osteoclasts; Receptors, CXCR4; Zoledronic Acid | 2007 |
Combined use of zoledronic acid and 153Sm-EDTMP in hormone-refractory prostate cancer patients with bone metastases.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Combined Modality Therapy; Diphosphonates; Humans; Imidazoles; Injections, Intravenous; Male; Metabolic Clearance Rate; Neoplasm Metastasis; Organometallic Compounds; Organophosphorus Compounds; Prostatic Neoplasms; Radioisotopes; Samarium; Zoledronic Acid | 2008 |
Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Bone Neoplasms; Breast Neoplasms; Cell Adhesion; Cell Cycle; Cell Movement; Clodronic Acid; Collagen; Diphosphonates; Dose-Response Relationship, Drug; Drug Combinations; Flow Cytometry; Fluorometry; Humans; Ibandronic Acid; Imidazoles; Laminin; Male; Matrix Metalloproteinases; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; Prostatic Neoplasms; Proteoglycans; Pyridines; Pyridinium Compounds; Tumor Cells, Cultured; Zinc; Zoledronic Acid | 2000 |